Effectiveness of Laser Acupuncture in Improving Arterial Stiffness Among Patients With Cardiorenal Metabolic Syndrome

Sponsor
National Yang Ming Chiao Tung University
Study ID
NCT07543211
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • laser acupuncture — OTHER
    Low-level laser therapy applied to acupuncture points as part of routine clinical treatment. No additional intervention is assigned for research purposes.

Study Details

Background: Cardio-renal metabolic syndrome (CRMS) is a vicious cycle of cardiac, renal, and metabolic disease, representing a high-risk for atherosclerosis. Laser acupuncture modulates vascular inflammation and improves endothelial function via low-level laser therapy (LLLT, \<500mW) at acupoints or musculoskeletal pain sites. Few studies have focused on CRMS populations. This study evaluates laser acupuncture effects on arterial stiffness in CRMS. Purpose: To assess the effects of improvement of laser acupuncture in patients with CRMS, and to evaluate its feasibility as supportive therapy. Methods: A single-group pre-post design is used. Participants are patients with CRMS receiving laser acupuncture at a Chinese medicine clinic in Taiwan. CRMS is interrelated by cardiac, renal, and metabolic disease. Inclusion criteria require diagnosis in ≥2 of 3 systems (cardiovascular, renal, or metabolic; n = 35). Laser acupuncture will be applied to bilateral BL40 for 12 weeks (1-3 sessions/week, 60mins/session). Pulse wave velocity(PWV) measured by Omron HBP- 8000 as the primary outcome for arterial stiffness. Paired t-tests and GEE will be used for analysis. Expected Results: PWV is expected to show significant improvement after intervention.

Key Dates

First listed
Apr 21, 2026
Start date
May 31, 2026
Status verified
Apr 2026
Primary completion
Aug 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
35 participants (estimated)

Primary Outcome Measure

Change in Pulse Wave Velocity (PWV) [ Time Frame: Baseline and after 12 weeks of treatment ]

Find similar trials

Nationwide
Chronic kidney disease trialsHypertension (high blood pressure) trialsNephrology trialsKidney disease trialsCardiology trialsHeart disease trials

Related Studies